Leaderboard Ad

Date

-

Time

2:00 pm - 3:00 pm

The first of a two-part series on gene therapy. Gene therapy has transformed the treatment landscape for hemophilia, though its path has not always been straightforward. In this webinar, we’ll review the promise of gene therapy, the expectations that surrounded its development, and its current status in the United States and Europe. We’ll discuss the importance of shared decision-making when considering gene therapy,  and look ahead to what future innovations may bring. There will be ample time for questions during the live Q&A.

 

Speakers:

Nathan T. Connell, MD, MPH, FACP
Dr. Nathan T. Connell is Associate Professor of Medicine at Harvard Medical School, Associate Director of the Boston Bleeding Disorders Center, and Vice Chair of Medicine at Mass General Brigham. He is an academic hematologist with expertise in inherited bleeding disorders, von Willebrand disease, hemostatic and antithrombotic stewardship, and systems-based hematology. His scholarship and leadership focus on translating subspecialty expertise into scalable models of care across health systems.

 

Brian O'Mahony
Brian O’Mahony is the Chief Executive of the Irish Haemophilia Society, President of the European Haemophilia Consortium and former President of the World Federation of Hemophilia. He is a Fellow of the Institute of Biomedical Sciences (UK) and a Fellow of the Academy of Clinical Science and Laboratory Medicine (Ireland) and an assistant adjunct Professor in Health Service Management in Trinity College, Dublin. Brian O’Mahony has severe hemophilia B.

 

Plain Language Summary of The Promise of Gene Therapy


In this webinar Dr Nathan Connell and Brian O’Mahony discussed the promise of gene therapy for hemophilia from their expert perspectives. Dr Connell is an Associate Professor of Medicine at Harvard Medical School and the Associate Director of the Boston Bleeding Disorders Center. He is a hematologist who cares for people with hemophilia, including shared decision-making around whether gene therapy is right for them. Brian O’Mahony is a lived experience expert who has personally received gene therapy for hemophilia B. As the Chief Executive of the Irish Haemophilia Society he is deeply involved in education and advocacy around access to gene therapy for other people with hemophilia. 


Why this matters 
Over recent decades as research into gene therapy progressed, excitement and expectations that it would transform hemophilia treatment also grew. Today, several hemophilia gene therapy products have been approved by the U.S. Food & Drug Administration (FDA), but not a lot of people have received them so far. For some people gene therapy can raise factor levels high enough and for long enough to convert their severe hemophilia into mild hemophilia, making a huge difference in their daily lives. Not everyone with hemophilia is eligible for gene therapy or can access it. The results can be difficult to predict, the long-term safety of these new treatments is not yet fully known, and other treatment options are increasingly available. The decision of whether gene therapy is right for an individual is a complicated one that must be taken through fully informed shared decision-making with their care team. 


The science of gene therapy for hemophilia 
Dr Connell provided an overview of the development of the different modern treatments for hemophilia from the first replacement factor products in the 1980s to non-factor agents starting in the late 2010s and gene therapy in the 2020s. He explained several different gene therapy technologies with a focus on gene transfer, used in current hemophilia gene therapies. In this approach a virus capsid, or shell, packages and delivers the factor 8 or factor 9 gene into specific cells in the liver that then make the factor VIII or factor IX protein and release it into the blood. The virus capsid, also called a viral vector, has been altered so it cannot cause an infection like most viruses do. The goal of gene transfer, sometimes called gene addition, is to add a functional factor 8 or 9 gene so that the liver can make enough factor VIII or IX protein for the whole body and lower the risk of bleeding. The person’s own genes are not altered or “fixed” by this 
kind of gene therapy. 


Dr Connell discussed several considerations regarding hemophilia gene therapies. He explained two main efficacy considerations (how much factor VIII or IX gets made and for how long): 

  • Different people with hemophilia experience different responses (making different amounts of factor) to gene therapy, some experience no real response (not making any more factor than before) 
  • For some people their factor levels increase and stay higher for several years. As these products are so new, we don’t know yet how long the effect can last. 


Safety considerations: 

  • Because these products are so new, we don’t know everything about their long-term safety yet. 
  • It might not be possible to give people a second dose of gene therapy if they need it, because their immune system might destroy it.


Who is gene therapy right for? 
Not everyone is eligible for gene therapy. Some people already have antibodies to the viral capsid that delivers the factor 8 or 9 gene to the liver. This means their immune system might destroy the viral vector and prevent the gene therapy from working. Other eligibility criteria include age, hemophilia severity, whether the person has or had an inhibitor, and how healthy their liver is. Dr Connell explained how each of these impact eligibility. 


Dr Connell discussed the burden that hemophilia can place on daily life. Several innovative new treatments, including gene therapy, aim to lighten this burden or even remove it entirely. Which treatment option is best for an individual depends on many things including their personal values and priorities and any challenges they may face. These may change over the different stages of a lifetime. Shared decision-making about treatment is an ongoing conversation between the individual and their care team, as circumstances and options evolve. Dr Connell outlined the model his team uses to approach shared decision-making and how they strive to empower people with hemophilia at every step along that path. He also acknowledged that structural racism, fears, and stigmas about treatment, insurance access, and other biases may present barriers to equitable access to treatment and care. 


What is it like to receive gene therapy? 
Brian O’Mahony related his personal journey from following the progress of gene therapy research, to considering it for himself, making the decision to go ahead with it, receiving the treatment as part of a clinical trial, and now reflecting on its impact on his life 80 months later. 
From childhood through his adult life, Brian experienced all the different treatment options for hemophilia B. He followed the progress of research into gene therapy for decades and advocated for access to clinical trials for people with hemophilia in Ireland, where he lives. His decision to participate in one such clinical trial was both personal and an extension of his advocacy work. He explained the factors he weighed in making that decision, what he hoped for, what he was concerned about, and how he prepared to face a result he could not predict. Brian outlined the medical outcomes used to measure the success of gene therapy and how they translate into meaningful changes in the life of a person with hemophilia. He also described the practical realities of preparing for and receiving the treatment, the many follow-up clinic visits in the first year, and the importance of lifelong monitoring of his safety and efficacy results. His own outcomes have been very positive: his physical health has improved, the burden of hemophilia on his life has decreased, and his participation in the clinical trial and sharing of his experiences has contributed to access to treatment options for other people with hemophilia.


Fully informed shared decision-making 
Brian discussed initiatives to optimize the education and empowerment of other community members in shared decision-making around gene therapy. Using the Irish Haemophilia Society approach as an example he stressed the importance of extensive education and reflection about this one-time irreversible treatment. The objective of their program is not to persuade or dissuade but to make sure each person with hemophilia makes a fully informed personal decision. They discuss the science of gene therapy, eligibility, short-term and long-term impacts on lifestyle (e.g., no alcohol for at least 1 year, follow-up visit requirements), possible efficacy results (factor levels, duration), and possible safety concerns (known and unknown). They encourage each individual to consider multiple decision drivers including: 

 

  • How well their hemophilia is currently being managed, for example how many bleeds they experience and how severe they are 
  • The current state of their joints 
  • How active they currently are and if there are barriers to them becoming more active 
  • Any issues with administration of their current treatment (e.g., needle phobia or difficulty accessing veins) 
  • Fatigue from the burden of living with hemophilia 
  • Access to other treatment options 


Brian emphasized the importance of setting and managing expectations. While gene therapy has the exciting potential for very positive impact on the life of a person with hemophilia, individual results are unpredictable, some safety issues remain unclear, and the treatment cannot be stopped or reversed once taken. Being mentally and socially prepared for all possible outcomes is critical. 


To learn more 
Brian and Dr Connell both mentioned several helpful resources in their presentations. Watch the full recording of this webinar to hear all the details presented by our experts, and to see the resources they recommend 
• Consult the large collection of NBDF gene therapy educational resources.  

• Download a guide to NBDF gene therapy and innovative therapies resources. 

• Demystify terms often used in discussing gene therapy and innovative therapies 
in this glossary

• Find answers to commonly asked questions about gene therapy 
 
• Create your own list of questions about gene therapy to discuss with your 
provider starting with these suggestions 

• Learn more about shared decision-making (SDM) and the WFH SDM tool 

• Explore a toolkit of clinical trial essentials for people with bleeding disorders 
considering participation in a trial 

• Read the NBDF Community Voices in Research (CVR) paper, Development of a 
haemophilia A gene therapy shared decision-making tool for clinicians 
 
• Read the NBDF Community Voices in Research (CVR) paper, Gene therapy 
preferences and informed decision-making: Results from a NHF CVR survey 
 

&nsbp;

&nsbp;